search
Back to results

Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis

Primary Purpose

Cholangitis, Complication

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
endoscopic retrograde biliary drainage
endoscopic nasobiliary drainage
Sponsored by
First People's Hospital of Hangzhou
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cholangitis focused on measuring cholangitis, endoscopic retrograde cholangiopancreatography, complication

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Obtention of a written informed consent; Patient with choledocholithiasis; Common bile duct stones are removed clearlly.

Exclusion Criteria:

No written informed consent; Combined with acute pancreatitis, acute cholangitis pre-ERCP; Patient under 18 or over 75 years.

Sites / Locations

  • Hangzhou First People's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

endoscopic retrograde biliary drainage

endoscopic nasobiliary drainage

Arm Description

Patients will undergo endoscopic retrograde biliary drainage (ERBD) with 8.5 F plastic stent with proximal flap when bile duct stones were removed clearly with ERCP. The stent will be taken out with endoscopy three months later if not discharge self-driven.

Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.

Outcomes

Primary Outcome Measures

Post-ERCP cholangitis
The rate and severity of post-ERCP cholangitis will compared between two groups.

Secondary Outcome Measures

adverse events
Number of participants with adverse events; type, frequency and intensity of adverse events.

Full Information

First Posted
November 1, 2015
Last Updated
May 21, 2016
Sponsor
First People's Hospital of Hangzhou
search

1. Study Identification

Unique Protocol Identification Number
NCT02594891
Brief Title
Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis
Official Title
Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis on Patients With choledocholithiasis--a Prospective Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Completed
Study Start Date
November 2015 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
First People's Hospital of Hangzhou

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Cholangitis is one of the main complications of endoscopic retrograde cholangiopancreatography (ERCP). Plastic biliary stent was used to prevent the occurrence of post-ERCP cholangitis, but the stent should be taken out 1-2 weeks after ERCP with endoscope again. 8.5 F plastic stent with proximal flap can discharge self-driven from biliary to the gut, it has the advantage of avoiding pulling stent out with endoscope again. The purpose of this study is to explore 8.5 F plastic stent with proximal flap on preventing post-ERCP cholangitis of ERCP in patients with choledocholithiasis.
Detailed Description
Since its introduction in 1968, endoscopic retrograde cholangiopancreatography (ERCP) has become a commonly performed endoscopic procedure, and the first choice in the management of choledocholithiasis. Although as an endoscopic minimally invasive procedure, there are still certain complications of ERCP, cholangitis is one of the main complications. In European and American countries, plastic biliary stent was used to prevent the occurrence of post-ERCP cholangitis, but the stent should be taken out 1-2 weeks after ERCP with endoscope again. In China endoscopic nasobiliary drainage is usually adopted to prevent post-ERCP cholangitis. Although nose bile duct was more convenient to pull out without endoscope again, but patients often feel nose pharynx ministry unwell obviously. 8.5 F plastic stent with proximal flap can discharge self-driven from biliary to the gut, it has the advantage of avoiding pulling stent out with endoscope again. The purpose of this study is to explore 8.5 F plastic stent with proximal flap on preventing post-ERCP cholangitis of ERCP in patients with choledocholithiasis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholangitis, Complication
Keywords
cholangitis, endoscopic retrograde cholangiopancreatography, complication

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
85 (Actual)

8. Arms, Groups, and Interventions

Arm Title
endoscopic retrograde biliary drainage
Arm Type
Experimental
Arm Description
Patients will undergo endoscopic retrograde biliary drainage (ERBD) with 8.5 F plastic stent with proximal flap when bile duct stones were removed clearly with ERCP. The stent will be taken out with endoscopy three months later if not discharge self-driven.
Arm Title
endoscopic nasobiliary drainage
Arm Type
Placebo Comparator
Arm Description
Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.
Intervention Type
Device
Intervention Name(s)
endoscopic retrograde biliary drainage
Intervention Description
A 8.5 F plastic stent with proximal flap (XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
Intervention Type
Device
Intervention Name(s)
endoscopic nasobiliary drainage
Intervention Description
A nose bile duct(XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
Primary Outcome Measure Information:
Title
Post-ERCP cholangitis
Description
The rate and severity of post-ERCP cholangitis will compared between two groups.
Time Frame
three months
Secondary Outcome Measure Information:
Title
adverse events
Description
Number of participants with adverse events; type, frequency and intensity of adverse events.
Time Frame
three months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Obtention of a written informed consent; Patient with choledocholithiasis; Common bile duct stones are removed clearlly. Exclusion Criteria: No written informed consent; Combined with acute pancreatitis, acute cholangitis pre-ERCP; Patient under 18 or over 75 years.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaofeng Zhang, M.S
Organizational Affiliation
First People's Hospital of Hangzhou
Official's Role
Study Director
Facility Information:
Facility Name
Hangzhou First People's Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
31006
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
22341094
Citation
ASGE Standards of Practice Committee; Anderson MA, Fisher L, Jain R, Evans JA, Appalaneni V, Ben-Menachem T, Cash BD, Decker GA, Early DS, Fanelli RD, Fisher DA, Fukami N, Hwang JH, Ikenberry SO, Jue TL, Khan KM, Krinsky ML, Malpas PM, Maple JT, Sharaf RN, Shergill AK, Dominitz JA. Complications of ERCP. Gastrointest Endosc. 2012 Mar;75(3):467-73. doi: 10.1016/j.gie.2011.07.010. No abstract available.
Results Reference
background

Learn more about this trial

Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis

We'll reach out to this number within 24 hrs